Compare GSK plc (GSK) vs Meta Platforms Inc (META) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

META stock trades at $673.95, up 1.95% today, with strong technical momentum and bullish moving averages. The company reported robust earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected, driven by revenue growth to $201.0B in 2025. Analyst sentiment is overwhelmingly positive, with a consensus price target of $807.84, though RSI levels indicate potential overbought conditions near-term.

The outlook remains favorable given META's AI advancements like Muse Spark and solid profitability, but risks include regulatory lawsuits and high capital expenditures. With 79% of analysts rating it Buy, the stock offers growth potential, though investors should monitor legal developments and valuation multiples.